iNexin™ (0.08% aCT1)
2021-OCLR-01b
Phase 1 small_molecule completed
Quick answer
iNexin™ (0.08% aCT1) for Dry Eye Disease is a Phase 1 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Dry Eye Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed